AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
April 23, 2024 06:00 ET
|
Averoa
Grenoble, France, 23rd April 2024 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, announces the submission of a marketing authorisation...
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
March 25, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
March 18, 2024 07:05 ET
|
Sequel Med Tech
Sequel’s twiist™ automated insulin delivery system receives FDA 510(k) clearance. Significant advancements for people with people with Type 1 diabetes.
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
March 14, 2024 15:11 ET
|
Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
March 13, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 13, 2024 ...
Dr. Lisandro Montalvo-Burke Joins Healthmap Solutions as Medical Director for Puerto Rico
February 13, 2024 08:00 ET
|
Healthmap Solutions
Healthmap Solutions, Inc. has named Lisandro Montalvo-Burke, MD as its new Medical Director in Puerto Rico.
Dialysis Market Surges Towards USD 198.2 Billion by 2033 | Driven by Rising Demand for Renal Replacement Therapy Solutions
February 06, 2024 04:42 ET
|
Market.Us
New York, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Dialysis Market value is projected to exceed USD 198.2 Billion by 2033, with a projected CAGR of 5.5% from 2024 to 2033. The...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
January 23, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive...
Renal function test market forecasting a US$1.6 billion illumination by 2030, with Persistence Market Research
January 22, 2024 02:00 ET
|
Persistence Market Research
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Renal Function Test Market: A Comprehensive Analysis Renal Function Tests are a series of diagnostic tests used to assess the functioning of the kidneys....
Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
January 18, 2024 10:45 ET
|
Spherix Global Insights
Exton, PA, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis patients at local dialysis clinics...